Physician profile
Mackenzie Armstrong
NPI 1225612385
$6,148.20
in general payments reported to CMS, 2019-2025
27 companies · $4,519 in 2025
The $4,519 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10.05 · 2023: $240 · 2024: $1,379 · 2025: $4,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913 · Consulting Fee: $1,125 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.16 |
| Consulting Fee | $1,125.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,323.35 | 2024-2025 | Tremfya |
| Ucb, INC. | $676.57 | 2023-2025 | Bimzelx, Briviact |
| Abbvie INC. | $663.16 | 2023-2025 | |
| Lilly USA, LLC | $453.48 | 2024-2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $236.67 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $192.36 | 2024-2025 | |
| Galderma Laboratories, L.P. | $169.22 | 2025 | Nemluvio |
| Astrazeneca Pharmaceuticals LP | $126.66 | 2024 | Breztri |
| Mylan Specialty L.P. | $124.98 | 2024 | Yupelri |
| Lundbeck LLC | $122.41 | 2025 | Rexulti |
| Abbott Laboratories | $122.10 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $121.32 | 2024 | Arexvy |
| Genzyme Corporation | $114.45 | 2025 | |
| Smith+Nephew, INC. | $108.33 | 2024 | Stravix Pl, Grafix, Stravix |
| Penumbra, INC. | $99.26 | 2025 | Indigo System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $85.46 | 2024-2025 | Otezla, Otezla |
| Medtronic, INC. | $85.20 | 2024 | Interstim |
| Idorsia Pharmaceuticals US INC | $57.32 | 2023 | Quviviq |
| Incyte Corporation | $56.50 | 2025 | Opzelura |
| Mayne Pharma Commercial LLC | $54.10 | 2025 | |
| Exact Sciences Corporation | $31.91 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.79 | 2025 | Spevigo |
| Organon LLC | $27.73 | 2025 | |
| Almirall LLC | $22.36 | 2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $18.13 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2025 | Sotyktu |
| Genentech USA, INC. | $10.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.